But that IPO stock-comp expense is largely attributable to R&D, so if you want to subtract that from the losses to look at a more cash-focused analysis you have to substract that cost from the R&D side as well.
Of the $3.95B total stock expense, $2.56B was from R&D, which suggests cash cost that quarter was more like $910m (still a lot!)